# Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

> **NCT03384316** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 11 (actual)

## Conditions studied

- Neoplasms
- Prostate Cancer
- Lung Cancer
- Breast Cancer
- Colon Cancer

## Interventions

- **BIOLOGICAL:** ETBX-051; adenoviral brachyury vaccine
- **BIOLOGICAL:** ETBX-061; adenoviral Mucin-1 (MUC1) vaccine
- **BIOLOGICAL:** ETBX-011; adenoviral Carcinoembryonic antigen (CEA) vaccine

## Key facts

- **NCT ID:** NCT03384316
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-31
- **Primary completion:** 2018-05-22
- **Final completion:** 2020-08-24
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2020-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03384316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03384316, "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03384316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*